UBS raised its price target on Buy-rated HEALTHSOUTH (NYSE: HLS) from $27 to $29.50 following strong Q4 results and aggressive ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE